Farmas USA

Tiene que irse por encima del dólar para que no la deslisten, verdad?

RGLS

son 30 dias sub 1 para recibir el aviso de la SEC y solo lleva creo que 23.

y luego tiene 6 meses de margen    hay tiempo

RGLS

Pero no dejes de cantar esos cortos...

Si quieres compartimos un momento escritorio y te enseño lo de subir gráficos. En mucho más fácil y rápido que el análisis técnico :D

CNAT dentro ayer, al acabar el tercer día

me actualizo el grafico semanal de XBI

Te los pado luego por privado. 😉😉

MRK

La noticia creo que ya la subí. Subo el análisis de Hartman.

phase III KEYNOTE-042 study met its primary endpoint of overall survival. This study compared the PD-1 antibody pembrolizumab to chemotherapy as first-line treatment for non-small cell lung cancer that expresses PD-L1 at a 1% cutoff. This stands in direct contrast to CheckMate-026, which failed to demonstrate an improvement in progression-free survival for nivolumab compared with chemotherapy.

This is a very big potential game changer. Pembrolizumab is already approved for first-line non-small cell lung cancer, but this was in a rather restricted population (those with a PD-L1 ≥50%). Disease with 1% or more PD-L1 expression likely represents the majority of patients. But now it's totally clear why one worked whereas the other didn't. Different populations? PD-L1 not being a good biomarker? Maybe pembrolizumab is actually better tha nivolumab? At this point, we really need the full data. In the meantime, MRK stands to benefit mightily with these data, which will very likely lead to approval.

TRIL (alguien la seguía creo)

update on two of its development programs, TT-621 and TTI-622.

Following preliminary positive results with TT-621 in patients with mycosis fungoides, Trillium plans to sharpen the focus to the near-effects on patients with CTCL and peripheral T-cell lymphoma (PTCL). Newly enrolled patients in the study will receive a standardized intra-subject dose intensification schedule to increase drug exposure. In addition, the duration of treatment will be increased to enable weekly continuation therapy. For TTI-622, the company is in the process of launching a two-part, open-label phase 1a/1b study in patients with advanced relapsed/refractory lymphoma or multiple myeloma. Dosing in the study is expected to start in the current quarter. The first part of the two-part study will be a dose-escalation phase. This part will evaluate the safety and identify the maximum tolerated dose. In the second part, the combination of TTI-622 and rituximab will be evaluated.